Mice with established herpes encephalitis were used to compare the effects of chemotherapy using three different nucleoside analogues. Encephalitis was produced by intranasal inoculation of a type 1 strain of herpes simplex virus. Without chemotherapy all mice died within 5 to 7 days of inoculation. Oral acyclovir (ACV) was a successful preventative measure if commenced within 2 days of inoculation but much less effective if the onset of treatment was further delayed. From the third day, when central nervous system infection had definitely become established, ACV only reduced mortality if given intraperitoneally (i.p.) at regular 6-hourly intervals. Comparison with bromovinyldeoxyuridine (BVdU) and the new nucleoside analogue dihydroxypropoxy-methylguanine (DHPG) using the same 6-hourly i.p. regimen revealed that BVdU was poorly effective, despite better activity in vitro, whereas DHPG was the most successful. Virus was rapidly eradicated from all parts of the brain by DHPG therapy, and by day 10, no infectious virus remained in the brains of treated mice, no virus antigens were observed and no trace of virus DNA could be detected in neural tissues by Southern blotting.
AndersonJ. R.,
FieldH. J.1983; The distribution of herpes simplex type 1 antigen in mouse central nervous system after different routes of inoculation. Journal of Neurological Sciences 60:181–195
AshtonW. T.,
KarkasJ. D.,
FieldA. K.,
TolmanR. L.1982; Activation by thymidine kinase and potent anti-herpetic activity of 2′-nor-2′-deoxyguanosine (2′-NDG). Biochemical and Biophysical Research Communications 108:1718–1721
BironK. K.,
NoglinJ. E.,
De MirandaP.,
ElionG. B.1982; Uptake, distribution and anabolism of acyclovir in herpes simplex virus infected mice. Antimicrobial Agents and Chemotherapy 21:44–50
DeclercqE.,
LuczakM.1975; Intranasal challenge of mice with herpes simplex virus: an experimental model for evaluation of the efficacy of antiviral drugs. Journal of Infectious Diseases 133: supplement A226–235
DeclercqE.,
DescampsU.,
De SomerP.,
BarrP. J.,
JonesA. S.,
WalkerR. T.1979; Pharmokinetics of E-5-(2-bromovinyl)-2′-deoxyuridine in mice. Antimicrobial Agents and Chemotherapy 16:234–236
DE ClercqE.,
ZhangZ.-X.,
SimI. S.1982; Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2′-deoxyuridine in mice. Antimicrobial Agents and Chemotherapy 22:421–425
EsiriM. M.1982; Herpes simplex encephalitis – an immunohistological study of the distribution of viral antigen within the brain. Journal of Neurological Sciences 54:209–266
FieldH. J.,
DE ClercqE.1981; Effects of oral treatment with acyclovir and bromovinyldeoxyuridine on the establishment and maintenance of latent herpes simplex virus infection in mice. Journal of General Virology 56:259–265
FieldH. J.,
NedenJ.1982; Isolation of bromovinyldeoxyuridine-resistant strains of herpes simplex virus and successful chemotherapy of mice infected with one such strain by using acyclovir. Antiviral Research 2:243–254
FieldH. J.,
BellS. E.,
ElionG. B.,
NashA. A.,
WildyP.1979; Effect of acycloguanosine treatment on acute and latent herpes simplex infections in mice. Antimicrobial Agents and Chemotherapy 15:554–561
GlazkoA. J.,
ChangT.,
DrachJ. C.1975; Species differences in the metabolic disposition of adenine arabinoside. In Adenine Arabinoside: an Antiviral Agent pp 111–113 Edited by
Pavan-LangstonD.BuchananR. A.,
AlfordC. A.Jr
New York: Raven Press;
HillT. J.,
FieldH. J.,
BlythW. A.1975; Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease. Journal of General Virology 28:341–353
KernE. R.,
RichardsJ. T.,
GlasgowL. A.,
OverallJ. C.,
DE MirandaP.1982; Optimal treatment of herpes simplex virus encephalitis in mice with oral acyclovir. American Journal of Medicine 73:125–131
LarssonA.,
BraunstromG.,
ObergB.1983; Reversal of the antiherpes activity of nucleoside analogues: a kinetic analysis in cell culture. Antimicrobial Agents and Chemotherapy (in press)
ReefschlagerJ.,
WutzlerP.,
ThielK.-D.,
BarwolffD.,
LangenP.,
SprossigM.,
RosenthalH. A.1982; Efficacy of (E)-5-(2-bromovinyl)-l-deoxyuridine against experimental herpes encephalitis in mice. Antiviral Research 2:255–265
RigbyP. W. J.,
DieckmannM.,
RhodesC.,
BergP.1977; Labelling DNA to high specific activity in vitro by nick translation with DNA polymerase I. Journal of Molecular Biology 113:237–251
SchaefferH. J.,
BeauchampL.,
De MirandaP.,
ElionG. B.,
BauerD. J.,
CollinsP.1978; 9-(2)Hydroxy-ethoxymethyl)guanine activity against viruses of the herpes group. Nature, London 272:583–585
SchinaziR. F.,
PetersJ.,
SokolM. K.,
NahmiasA. J.1983; Therapeutic activities of l-(2)fluoro-2′-deoxy-β-d-arabinofuranosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus. Antimicrobial Agents and Chemotherapy 24:95–103
WhitleyR. J.,
SoongS. J.,
DolinR.,
GalassoG. J.,
Ch’ienL. T.,
AlfordC. A.
The Collaborative Study Group 1977; Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. New England Journal of Medicine 297:289–294
WhitleyR. J.,
SoongS. J.,
HirschM. S.1981; Herpes simplex encephalitis. Vidarabin therapy and diagnostic problems. New England Journal of Medicine 304:313–318